Thyagaraju Adinarayan

August 11, 2022 | Daily Business Review

Zantac was a once-popular antacid that has drawn a flurry of U.S. personal-injury lawsuits alleging it causes cancer.

By Thyagaraju Adinarayan and Lisa Pham

3 minute read

May 24, 2022 | Daily Business Review

Snap and platforms such as Facebook and Google are competing for advertising dollars at a challenging time.

By Subrat Patnaik and Thyagaraju Adinarayan

3 minute read

February 18, 2022 | Daily Business Review

JPMorgan's equity team has been among the most optimistic voices on Wall Street about the outlook for global stock markets.

By Nikos Chrysoloras and Thyagaraju Adinarayan

2 minute read

February 09, 2022 | Daily Business Review

Peloton was a darling of investors early in the pandemic when fitness fans, cooped up at home, flocked to its sleek gadgets and subscription services.

By Jeran Wittenstein and Thyagaraju Adinarayan

3 minute read

February 03, 2022 | Daily Business Review

It's not the first time Meta shares have dropped dramatically. The stock plunged 19% in July 2018 on a slowdown in user growth, translating to a about $120 billion decline in market capitalization.

By Thyagaraju Adinarayan and Jan-Patrick Barnert

2 minute read

November 30, 2021 | Daily Business Review

From Elon Musk's Tesla Inc. to Reed Hastings' Netflix Inc., tech firms led by their founder have mostly beaten the broader market by a huge margin.…

By Thyagaraju Adinarayan and Jeran Wittenstein

4 minute read